Matched FFPE and ctDNA Analysis using Illumina TruSightTumor 170 NGS Assay

Technical feasibility for utilizing TruSightTumor 170 NGS assay (+UMIs) to analyze ctDNA

This presentation, given at the BioPharma Innovation Conference in September 2018, highlights Q2 Solutions' collaboration with Illumina and an additional pharma partner, where we have demonstrated technical feasibility for utilizing TruSight Tumor 170 Next Generation Sequencing (NGS) assay in the presence of UMIs to enable low frequency mutation detection (down to ~0.4%) in circulating-tumor DNA.

Download this presentation to learn more.